Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.
Miyoshi Y, Uemura H, Umemoto S, Sakamaki K, Morita S, Suzuki K, Shibata Y, Masumori N, Ichikawa T, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Harada M, Kubota Y. Miyoshi Y, et al. Among authors: uemura h. BMC Cancer. 2014 Sep 26;14:717. doi: 10.1186/1471-2407-14-717. BMC Cancer. 2014. PMID: 25256077 Free PMC article.
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).
Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H. Matsubara N, et al. Among authors: uemura h. Jpn J Clin Oncol. 2014 Dec;44(12):1216-26. doi: 10.1093/jjco/hyu149. Epub 2014 Oct 15. Jpn J Clin Oncol. 2014. PMID: 25320340 Free PMC article. Clinical Trial.
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Satoh T, Uemura H, Tanabe K, Nishiyama T, Terai A, Yokomizo A, Nakatani T, Imanaka K, Ozono S, Akaza H. Satoh T, et al. Among authors: uemura h. Jpn J Clin Oncol. 2014 Dec;44(12):1206-15. doi: 10.1093/jjco/hyu148. Epub 2014 Oct 1. Jpn J Clin Oncol. 2014. PMID: 25425730 Free PMC article. Clinical Trial.
Androgen deprivation therapy prevents bladder cancer recurrence.
Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, Ueki T, Udagawa K, Kitami K, Moriyama M, Miyoshi Y, Tsuchiya F, Ikeda I, Kobayashi K, Sato M, Morita S, Noguchi K, Uemura H. Izumi K, et al. Among authors: uemura h. Oncotarget. 2014 Dec 30;5(24):12665-74. doi: 10.18632/oncotarget.2851. Oncotarget. 2014. PMID: 25557268 Free PMC article.
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, Miyazaki J, Suzuki K, Okihara K, Arai Y, Kamba T, Kato M, Nakai Y, Furuse H, Kume H, Ide H, Kitamura H, Yokomizo A, Kimura T, Tomita Y, Ohno K, Kakehi Y. Nozawa M, et al. Among authors: uemura h. Int J Clin Oncol. 2015 Oct;20(5):1026-34. doi: 10.1007/s10147-015-0820-9. Epub 2015 Mar 26. Int J Clin Oncol. 2015. PMID: 25809824 Clinical Trial.
Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer.
Miyoshi Y, Uemura H, Umemoto S, Sakamaki K, Taguri M, Suzuki K, Shibata Y, Masumori N, Ichikawa T, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Harada M, Kubota Y. Miyoshi Y, et al. Among authors: uemura h. Prostate. 2016 Mar;76(4):376-82. doi: 10.1002/pros.23129. Epub 2015 Nov 30. Prostate. 2016. PMID: 26616365
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
Akaza H, Uemura H, Tsukamoto T, Ozono S, Ogawa O, Sakai H, Oya M, Namiki M, Fukasawa S, Yamaguchi A, Uemura H, Ohashi Y, Maeda H, Saito A, Takeda K, Naito S. Akaza H, et al. Among authors: uemura h. Int J Clin Oncol. 2016 Aug;21(4):773-782. doi: 10.1007/s10147-016-0952-6. Epub 2016 Jan 21. Int J Clin Oncol. 2016. PMID: 26793974 Free PMC article. Clinical Trial.
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H, Kondo K, Kawahara T, Kaneta T, Tateishi U, Ueno D, Namura K, Kobayashi K, Miyoshi Y, Yumura Y, Makiyama K, Hayashi N, Hasumi H, Osaka K, Yokomizo Y, Teranishi JI, Hattori Y, Inoue T, Uemura H, Yao M, Nakaigawa N. Ito H, et al. Among authors: uemura h. Cancer Chemother Pharmacol. 2017 May;79(5):855-861. doi: 10.1007/s00280-017-3275-z. Epub 2017 Mar 22. Cancer Chemother Pharmacol. 2017. PMID: 28331985
1,355 results